MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Checkpoint Therapeutics Inc

Closed

SectorHealthcare

4.04 0.25

Overview

Share price change

24h

Current

Min

4.02

Max

4.04

Key metrics

By Trading Economics

Employees

23

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+31.19% upside

Dividends

By Dow Jones

Next Earnings

9 maj 2025

Market Stats

By TradingEconomics

Market Cap

207M

Previous open

3.79

Previous close

4.04

News Sentiment

By Acuity

50%

50%

180 / 386 Ranking in Healthcare

Checkpoint Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 mar 2025, 10:23 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14 gru 2024, 00:24 UTC

Major Market Movers

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25 lip 2024, 13:02 UTC

Major Market Movers

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10 mar 2025, 02:12 UTC

Acquisitions, Mergers, Takeovers

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 mar 2025, 02:12 UTC

Acquisitions, Mergers, Takeovers

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 mar 2025, 02:11 UTC

Acquisitions, Mergers, Takeovers

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 mar 2025, 02:11 UTC

Acquisitions, Mergers, Takeovers

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 mar 2025, 02:10 UTC

Acquisitions, Mergers, Takeovers

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 mar 2025, 02:10 UTC

Acquisitions, Mergers, Takeovers

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 mar 2025, 02:06 UTC

Acquisitions, Mergers, Takeovers

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Peer Comparison

Price change

Checkpoint Therapeutics Inc Forecast

Price Target

By TipRanks

31.19% upside

12 Months Forecast

Average 5.3 USD  31.19%

High 7 USD

Low 4.1 USD

Based on 3 Wall Street analysts offering 12 month price targets forCheckpoint Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Sentiment

By Acuity

180 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

$

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.